2023-506163-34-00CompletedPhase 3
Efficacy and safety of the proposed biosimilar PERT-IJS versus EU-Perjeta® along with trastuzumab and chemotherapy (carboplatin and docetaxel) as neoadjuvant treatment in chemotherapy naïve patients with early stage or locally advanced HR negative and HER2 positive breast cancer
Source: EU CTIS (euclinicaltrials.eu) · Last updated 27 Nov 2023
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 46 (actual)
- First submitted
- 28 Jul 2023
- Start date
- 24 Nov 2023
- Lead sponsor
- Biocon Biologics UK Limited
- EU CT number
- 2023-506163-34-00
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 46
- 10 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (10)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Wojewodzki Szpital Specjalistyczny W Bialej Podlaskiej | Biala Podlaska | Poland | Completed |
| Szpital Specjalistyczny Im. Ludwika Rydygiera W Krakowie Sp. z o.o. | Cracow | Poland | Completed |
| Pratia S.A. | Cracow | Poland | Completed |
| Instytut MSF Sp. z o.o. | Lodz | Poland | Completed |
| Centra Medyczne Medyceusz Sp. z o.o. | Lodz | Poland | Completed |
| Mruk-Med I Sp. z o.o. | Rzeszów | Poland | Completed |
| Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy | Warsaw | Poland | Completed |
| Spital Clinic Militar De Urgenta Dr. Constantin Papilian Cluj Napoca | Cluj-Napoca | Romania | Completed |
| Centrul De Oncologie SF Nectarie S.R.L. | Craiova | Romania | Completed |
| Sigmedical Services S.R.L. | Suceava | Romania | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.